The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, outlines data obtained from a Phase II clinical trial investigating the safety and efficacy of olutasidenib, an IDH1 inhibitor, in patients with relapsed/ refractory (R/R) IDH1-mutated acute myeloid leukemia (AML). Dr de Botton discusses the overall response rate (ORR) and complete remission (CR) plus CR with partial hematologic recovery (CR+CRh) rate observed, which were 48% and 35%, respectively. Overall, olutasidenib was well tolerated and had an encouraging safety profile. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant/Research Support: Forma, Auron, Foghorn, Consultant: Forma, Auron, Servier, BMS, AbbVie, Jazz, Astellas Speaker’s bureau: Forma, Auron, Servier, BMS, AbbVie, Jazz, Astellas.
